Oli Rayner
Overview
Explore the profile of Oli Rayner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flatau T, Greenfield J, Dickie B, Rayner O, Matthews H, Wise J
Pharmaceut Med
. 2022 Aug;
36(5):279-286.
PMID: 35953655
Life science research and development (R&D) companies are all too aware of the importance of patient perspectives but also of the barriers to engaging directly with patients, not least compliance,...
2.
Rosenfeld M, Rayner O, Smyth A
Cochrane Database Syst Rev
. 2020 Sep;
9:CD001912.
PMID: 32997797
Background: Staphylococcus aureus causes pulmonary infection in young children with cystic fibrosis. Prophylactic antibiotics are prescribed hoping to prevent such infection and lung damage. Antibiotics have adverse effects and long-term...
3.
Abroshan M, Alaa A, Rayner O, van der Schaar M
J Cyst Fibros
. 2020 Feb;
19(1):6-8.
PMID: 32000972
No abstract available.
4.
Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials
Davies G, Rowbotham N, Smith S, Elliot Z, Gathercole K, Rayner O, et al.
J Cyst Fibros
. 2019 Nov;
19(3):499-502.
PMID: 31735561
In a recent James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF) the top priority clinical research question was: "What are effective ways of simplifying the treatment burden of...
5.
Smyth R, Rayner O
Cochrane Database Syst Rev
. 2017 May;
5:CD000406.
PMID: 28470972
Background: Poor nutrition occurs frequently in people with cystic fibrosis and is associated with other adverse outcomes. Oral calorie supplements are used to increase total daily calorie intake and improve...
6.
Rouse C, Mistry P, Rayner O, Nickless J, Wan M, Southern K, et al.
Int J Pharm Pract
. 2016 Sep;
25(5):326-334.
PMID: 27633317
Background: The palatability of flucloxacillin oral liquid is poor. Parents/carers use strategies to aid the administration of poorly palatable medicines. Aim: To assess views on the palatability of flucloxacillin oral...
7.
Batchelor H, Rayner O, Nickless J, Wan M, Southern K, Rose C
Arch Dis Child
. 2016 Aug;
101(9):e2.
PMID: 27540213
Aim: Palatability of flucloxacillin is poor, yet is used long-term in the management of children with cystic fibrosis (CF). Strategies to aid administration of unpalatable medicines have been reported, however...
8.
Smyth R, Rayner O
Cochrane Database Syst Rev
. 2014 Nov;
(11):CD000406.
PMID: 25363148
Background: Poor nutrition occurs frequently in people with cystic fibrosis (CF) and is associated with other adverse outcomes. Oral calorie supplements are used to increase total daily calorie intake and...